Menu
Detect germline and somatic mutations (SNVs, Indels, gene amplifications/deletions and exon-level CNVs) in up to 28 HRR genes involved in the etiology of HRD, including BRCA1 and BRCA2, with a targeted sequencing approach.
* Only available for RUO applications
Reduce hands-on time with one universal*, automated protocol for robust sequencing.
Match cancer molecular profiles to the latest evidence with OncoPortal™ Knowledge Base*.
Quickly prepare clear, comprehensive reports on HRD status*.
Universal genomic integrity assessment
Sensitive SNV and Indel detection
Reliable CNV analysis
Robust variant annotation
GIInger™ demonstrated high analytical concordance to centralized reference methods for HRD assessment in ovarian cancer (92.91% overall percent agreement)².
Identify critical gene amplification/deletion and exon-level copy number variation (CNV) events associated with HRD status, including BRCA1/2 or PTEN deletions and CCNE1 amplification. Our CNV calling algorithm adapts to experimental conditions and performs double normalization to call CNVs missed by other tools.
| MSK-ACCESS® powered with SOPHiA DDM™ | Adapt existing SOPHiA GENETICS solid tumor applications to liquid biopsy | Custom liquid biopsy applications tailored to your needs | |
|---|---|---|---|
| Lorem ipsum | Lorem ipsum dolor sit amet, consectetur | Lorem ipsum dolor sit amet, consecdolor sit amet, consect | Proin dictum aliquam hendrerit. Quisque tortor nulla |
| Pellentesque nec | Lorem ipsum dolor sit amet, consectetur | Lorem ipsum dolor sit amet, consecdolor sit amet, consect | Proin dictum aliquam hendrerit. Quisque tortor nulla |
| Aenean eros orci | Lorem ipsum dolor sit amet, consectetur | Lorem ipsum dolor sit amet, consecdolor sit amet, consect | Proin dictum aliquam hendrerit. Quisque tortor nulla |
| Proin non mi diam | Lorem ipsum dolor sit amet, consectetur | Lorem ipsum dolor sit amet, consecdolor sit amet, consect | Proin dictum aliquam hendrerit. Quisque tortor nulla |
“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.
We believe our scientific expertise, combined with AI-enabled technologies and data-driven solutions enabled by SOPHiA GENETICS, presents a unique opportunity to fundamentally transform the journey of cancer patients through non-invasive cancer analysis, predictive genomic testing, and effective precision medicine”.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
